12/17/2013 8:19:34 AM
European regulators are due to decide this week whether or not to recommend approval of a new multiple sclerosis pill from Teva Pharmaceutical Industries, according to a document published on Tuesday. The European Medicines Agency, which has started publishing agendas for its scientific meetings, listed Teva's laquinimod among new medicines to be considered at the December 16-19 meeting of the Committee for Medicinal Products for Human Use (CHMP). Decisions from the monthly meetings of the CHMP are normally made public on the following Friday, which would be December 20.
Help employers find you! Check out all the jobs and post your resume.
comments powered by